Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.8400
- TODAY'S CHANGE (%)-0.0200 (-0.5181%)
- Bid / Lots3.6100/ 2
- Ask / Lots3.9100/ 5
- Open / Previous Close3.9100 / 3.8600
- Day Range
- 52 Week Range
- Volume458,171
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 6290 | 3.825 |
| 09:34 ET | 438 | 3.865 |
| 09:36 ET | 100 | 3.88 |
| 09:38 ET | 2486 | 3.94 |
| 09:39 ET | 320 | 3.92 |
| 09:41 ET | 500 | 3.965 |
| 09:43 ET | 500 | 3.95 |
| 09:45 ET | 300 | 3.9574 |
| 09:48 ET | 1000 | 3.9357 |
| 09:50 ET | 853 | 3.945 |
| 09:52 ET | 2904 | 3.94 |
| 09:54 ET | 400 | 3.94 |
| 09:56 ET | 400 | 3.94 |
| 09:57 ET | 9487 | 3.97 |
| 09:59 ET | 500 | 3.9761 |
| 10:01 ET | 989 | 3.96 |
| 10:03 ET | 100 | 3.96 |
| 10:06 ET | 6813 | 3.9701 |
| 10:08 ET | 829 | 3.96 |
| 10:10 ET | 100 | 3.96 |
| 10:12 ET | 2850 | 3.96 |
| 10:15 ET | 500 | 3.95 |
| 10:17 ET | 1300 | 3.95 |
| 10:19 ET | 4685 | 3.9401 |
| 10:21 ET | 1300 | 3.93 |
| 10:24 ET | 2800 | 3.905 |
| 10:26 ET | 100 | 3.905 |
| 10:30 ET | 100 | 3.895 |
| 10:32 ET | 172 | 3.88 |
| 10:33 ET | 200 | 3.88 |
| 10:35 ET | 504 | 3.86 |
| 10:37 ET | 700 | 3.8502 |
| 10:39 ET | 100 | 3.85 |
| 10:42 ET | 200 | 3.85 |
| 10:44 ET | 100 | 3.85 |
| 10:46 ET | 754 | 3.845 |
| 10:48 ET | 420 | 3.84 |
| 10:50 ET | 200 | 3.83 |
| 10:51 ET | 1100 | 3.8157 |
| 10:53 ET | 2400 | 3.807 |
| 10:55 ET | 2453 | 3.8 |
| 10:57 ET | 100 | 3.78 |
| 11:00 ET | 450 | 3.7714 |
| 11:02 ET | 2401 | 3.8 |
| 11:04 ET | 360 | 3.8 |
| 11:06 ET | 100 | 3.79 |
| 11:08 ET | 300 | 3.8 |
| 11:09 ET | 600 | 3.8 |
| 11:11 ET | 100 | 3.805 |
| 11:13 ET | 1623 | 3.8 |
| 11:18 ET | 500 | 3.78 |
| 11:22 ET | 600 | 3.79 |
| 11:24 ET | 300 | 3.8 |
| 11:26 ET | 595 | 3.8 |
| 11:27 ET | 100 | 3.8 |
| 11:31 ET | 400 | 3.79 |
| 11:33 ET | 200 | 3.8 |
| 11:36 ET | 339 | 3.78 |
| 11:38 ET | 2329 | 3.78 |
| 11:40 ET | 200 | 3.785 |
| 11:42 ET | 16609 | 3.8 |
| 11:44 ET | 500 | 3.805 |
| 11:45 ET | 433 | 3.8 |
| 11:54 ET | 100 | 3.81 |
| 11:56 ET | 1800 | 3.8 |
| 12:02 ET | 2200 | 3.795 |
| 12:03 ET | 19462 | 3.7999 |
| 12:05 ET | 14010 | 3.79 |
| 12:07 ET | 100 | 3.79 |
| 12:14 ET | 11308 | 3.7786 |
| 12:16 ET | 1283 | 3.76 |
| 12:18 ET | 525 | 3.76 |
| 12:25 ET | 14606 | 3.71 |
| 12:27 ET | 939 | 3.72 |
| 12:36 ET | 2008 | 3.705 |
| 12:38 ET | 100 | 3.695 |
| 12:39 ET | 2389 | 3.7 |
| 12:43 ET | 1136 | 3.7 |
| 12:45 ET | 2117 | 3.695 |
| 12:48 ET | 6297 | 3.7 |
| 12:52 ET | 134 | 3.705 |
| 12:54 ET | 1983 | 3.68 |
| 12:56 ET | 100 | 3.68 |
| 12:57 ET | 59593 | 3.688 |
| 12:59 ET | 32351 | 3.755 |
| 01:01 ET | 24136 | 3.8 |
| 01:03 ET | 45016 | 3.79 |
| 01:10 ET | 471 | 3.785 |
| 01:12 ET | 100 | 3.78 |
| 01:14 ET | 100 | 3.78 |
| 01:15 ET | 100 | 3.78 |
| 01:17 ET | 2400 | 3.79 |
| 01:19 ET | 4799 | 3.81 |
| 01:26 ET | 100 | 3.8 |
| 01:28 ET | 1491 | 3.805 |
| 01:30 ET | 100 | 3.805 |
| 01:33 ET | 300 | 3.81 |
| 01:35 ET | 100 | 3.81 |
| 01:44 ET | 321 | 3.815 |
| 01:46 ET | 520 | 3.83 |
| 01:51 ET | 100 | 3.83 |
| 01:57 ET | 200 | 3.825 |
| 02:00 ET | 300 | 3.8146 |
| 02:09 ET | 1200 | 3.83 |
| 02:11 ET | 1619 | 3.84 |
| 02:18 ET | 1358 | 3.825 |
| 02:20 ET | 387 | 3.8118 |
| 02:24 ET | 100 | 3.82 |
| 02:26 ET | 145 | 3.8298 |
| 02:27 ET | 607 | 3.8 |
| 02:29 ET | 100 | 3.81 |
| 02:31 ET | 7703 | 3.82 |
| 02:33 ET | 100 | 3.815 |
| 02:36 ET | 100 | 3.8153 |
| 02:38 ET | 1296 | 3.82 |
| 02:40 ET | 300 | 3.815 |
| 02:51 ET | 1426 | 3.8 |
| 02:56 ET | 100 | 3.8 |
| 02:58 ET | 100 | 3.79 |
| 03:03 ET | 600 | 3.79 |
| 03:05 ET | 100 | 3.79 |
| 03:07 ET | 200 | 3.79 |
| 03:09 ET | 3706 | 3.81 |
| 03:12 ET | 100 | 3.805 |
| 03:14 ET | 300 | 3.81 |
| 03:18 ET | 100 | 3.81 |
| 03:21 ET | 400 | 3.82 |
| 03:23 ET | 100 | 3.82 |
| 03:25 ET | 100 | 3.82 |
| 03:32 ET | 507 | 3.8 |
| 03:38 ET | 100 | 3.8 |
| 03:39 ET | 100 | 3.805 |
| 03:41 ET | 1700 | 3.815 |
| 03:43 ET | 200 | 3.815 |
| 03:45 ET | 649 | 3.81 |
| 03:52 ET | 123 | 3.805 |
| 03:56 ET | 7879 | 3.8299 |
| 03:57 ET | 1924 | 3.815 |
| 03:59 ET | 4843 | 3.84 |
May 29, 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 8, 2024
May 6, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer, from 7:57AM ET on Monday May 06, 2024 by Dow Jones
7:57AM ET on Monday May 06, 2024 by Dow JonesDJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:48AM ET on Monday May 06, 2024 by Dow Jones
6:48AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 229.3M | -7.6x | --- |
Design Therapeutics Inc | 228.8M | -3.9x | --- |
Eliem Therapeutics Inc | 224.3M | -15.6x | --- |
Opthea Ltd | 224.2M | -1.1x | --- |
XBiotech Inc | 220.8M | -6.9x | --- |
Acrivon Therapeutics Inc | 238.4M | -2.7x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
